Plasma glial fibrillary acidic protein levels are a sensitive biomarker for amyloid-ß pathology in Alzheimer’s disease

Takeaway

  • In Alzheimer’s disease, plasma glial fibrillary acidic protein levels may be a better biomarker of amyloid-β pathology than cerebrospinal fluid levels, especially in preclinical disease.

Why this matters

  • Glial fibrillary acidic protein is a marker of reactive astrogliosis that is elevated in the cerebrospinal fluid and blood of people with Alzheimer’s disease.

  • This study was the first to examine whether elevations in plasma glial fibrillary acidic protein levels occur across the entire Alzheimer’s disease continuum; the findings could help to facilitate the detection of Alzheimer’s disease, particularly at the preclinical stage. Earlier detection would permit timely interventions and ultimately better outcomes in Alzheimer’s disease.